Abstract |
| Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock, Daniel C. Chan, Rita Ghosh and Addanki P. Kumar. Downregulation of ribosomal protein rpS6 overcomes radioresistance in prostate cancer; 2015 Apr. (Proceedings of American Association for Cancer Research).
|
| Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock,Rita Ghosh and Addanki P. Kumar. Nexrutine? modulates PI3K/mTOR and NF?B signaling to target radioresistance in prostate cancer; 2014 Nov. (16th Annual South Padre Conference on Advances in Cell Signaling, Cancer Prevention and Therapy).
|
| Amanda R. Mu?oz, James W. Freeman, & Addanki P. Kumar. Elucidating the mechanism of the STAT3/NF-?B/EP4 signaling axis in pancreatic cancer; 2014 Nov. (16th Annual South Padre Conference on Advances in Cell Signaling, Cancer Prevention).
|
| Yun, HY., Xie, J., Batth, IS., Li, R., Ghosh, R., Kumar, AP. ER-β/Sp/NFκB/FLIP axis: Potential therapeutic target in prostate cancer; 2014 Nov. (Greehey CCRI 10th Anniversary Symposium, San Antonio).
|
| Yun, HY., Xie, J., Batth, IS., Li, R., Ghosh, R., Kumar. Potential therapeutic target in prostate cancer; 2014 Oct. (21th Annual Graduate Student Symposium, San Antonio).
|
| Yun, HY., Xie, J., Batth, IS., Li, R., Ghosh, R., Kumar. ER-β/Sp/NFκB/FLIP axis: Potential therapeutic target in prostate cancer; 2014 Oct. (16th Annual South Padre Conference on advances in cell signaling cancer prevention and therapy, South Padre Island).
|
| Divya Chakravarthy, Carolina B Livi, Jingjing Gong, Robert R Reddick, Rosa F Hwang, Addanki P Kumar. SPHK1-GLI-COL1A1 axis contributes to pancreatic stellate and cancer cell crosstalk: potential therapeutic avenue; 2014 Jul. (Aspen Cancer Conference).
|
| Chakravarthy, D., Gong, J., Reddick, R., Hwang, FR., Kumar, AP. Targeting desmoplasia in pancreatic cancer; 2014 May. (Cellular and Structural Biology Retreat).
|
| Batth, I., Meng, P., Bedolla, R., Reddick, RE, Kumar, AP. RON-mediated hijacking of AR signaling in androgen-independent prostate cancer; 2014 May. (Cellular and Structural Biology Retreat, San Antonio).
|
| Batth, I., Gong, J., Kumar, AP. Novel interaction between FLIP/DAPK: role for RON in androgen-independent prostate cancer; 2014 May. (Cellular and Structural Biology Retreat, San Antonio).
|
| Amanda R. Mu?oz, James W. Freeman, & Addanki P. Kumar. Elucidating the mechanism of the STAT3/NF-κB/EP4 signaling axis in pancreatic cancer; 2014 Apr. (16th Annual South Padre Conference on Advances in Cell Signaling, Cancer Prevention).
|
| Batth, I., Meng, P., Bedolla, R., Reddick, RE., Kumar, AP. RON-mediated hijacking of AR signaling in androgen-independent prostate cancer; 2014 Apr. (105th American Association for Cancer Research Annual Meeting, San Diego).
|
| Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock,
Rita Ghosh and Addanki P. Kumar. Nexrutine? modulates PI3K/mTOR and NF?B signaling to target radioresistance in prostate cancer; 2014 Jan. (Pharmacology symposium 2014).
|
| Amanda R Munoz, Jingjing Gong, Divya Chakravarthy, Daniel E Chan, James W Freeman, Rita Ghosh, and Addanki P Kumar. Targeting the Stat3/NF-κB/EP4 signaling axis through combination treatment with Nexrutine and Gemcitabine for pancreatic cancer; 2014 Jan. (AACRPancreatic Cancer: Innovations in Research and Treatment, New Orleans, LA,).
|
| Amanda R. Mu?oz, Jingjing Gong, Divya Chakravarthy, Daniel E. Chan, James W. Freeman, Rita Ghosh, and Addanki P. Kumar. Targeting the Stat3/NF-κB/EP4 signaling axis through combination treatment with Nexrutine and Gemcitabine for pancreatic cancer (AACR Pancreatic Cancer: Innovations in Research and Treatment); 2014 Jan.
|
| Divya Chakravarthy, Jingjing Gong, Rosa F Hwang, and Addanki P Kumar. Targeting desmoplasia in pancreatic cancer; 2014 Jan. (Cellular and Structural Biology Retreat, San Antonio).
|
| Batth IS, Gong J, Kumar, Ph.D. AP. Novel interaction between FLIP/DAPK: role for RON in androgen-independent prostate cancer; 2013 Apr. (American Association for Cancer Research 104th Annual Meeting, Washington, DC).
|
Dissertation/Thesis |
| Divya Chakravarthy. Palmatine in pancreatic stellate cell and cancer cell interaction 2015. |
| Izhar Singh Batth. New roles for RON in prostate cancer 2014. |
| Jingjing Gong. NFKB/STAT3/COX-2 Signaling axis: Novel target for pancreatic cancer 2013. |
Journal Article |
| Kumar AP. Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation Cancer Letters 2018 Oct;433:232-241.
|
| Kumar AP. BRCA1 interacting protein COBRA1 facilitates adaptation to castrate resistant growth conditions International Journal of Molecular Sciences 2018 Jul;19(7):1-12.
|
| Kumar AP, D Chakravarthy, A Munoz, A Su, RF Hwang, BR Keppler, DE Chan, G Halff, R Ghosh. Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1 Cancer Letters 2018 Apr;419:103-115.
|
| Kumar AP. Single cell RNA Seq reveal subpopulation of prostate cancer cells Cancer Research 2018 Feb;78:853-864.
|
| Zhang Y, Li L, Wang J, Cheng W, Zhang J, Li X, Zhang Z, Gong J, Ghosh R, Kumar AP, Xie J. Combination of Nexrutine and Docetaxel suppresses NFκB-mediated activation of c-FLIP MOLECULAR CARCINOGENESIS 2017 May;.
|
| Huang G, Osmulski PA, Bouamar H, Mahalingam D, Lin CL, Liss MA, Kumar AP, Chen
CL, Thompson IM, Sun LZ, Gaczynska ME, Huang TH. TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts Oncotarget 2016 Nov;7(47):77124-77137.
|
| Zhao S, Chen C, Chang K, Karnad A, Jagirdar J, Kumar AP, Freeman JW. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy Clinical Cancer Research 2016 Nov;22:5592-5604.
|
| Batth, IS., Yun, H., Meng, P., Osmulski, P., Huang, TH., Bedolla, R., Reddick, RE., Kumar AP. Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer Oncotarget 2016 Jan;.
|
| Hambright HG, Meng, P, Kumar AP and Ghosh R. Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget (in press) Oncotarget 2015 Jan;.
|
| Swanson, GP., Jones WE., Ha, CS., Jenkins, CA., Kumar AP and Basler, J. Tolerances of Phellodendron amurense bark extract (Nexrutine) in human prostate cancer patients. Phytotherapy Research doi: 10.1002/ptr. 5221. [Epub ahead of print] PMID:25205619 Phytotherapy Research 2015 Jan;.
|
| Yun, HY., Xie, J., Olumi, AF., Ghosh, R., Kumar AP. Activation of AKR1C1/ERB induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity Oncotarget 2015 Jan;.
|
| Kumar AP. Combined targeting of Stat3/NF B/Cox-2/EP4 for effective management of pancreatic cancer Clinical Cancer Research 2014 Jan;20.
|
| Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP AND Ghosh R. NQO1 suppresses NF-kB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis Cancer Research 2014 Jan;74(5644):5644-5655.
|
| Gong, JJ., Xie, J., Bedolla, R., Rivas, P., Chakravarthy, D. Freeman, JW., Reddick, R., Kopetz, S., Peterson, A., Wang, H., Fischer, SM and Kumar AP. Combined targeting of Stat3/NFkB/Cox-2/EP4 for effective management of pancreatic cancer Clinical Cancer Research (in press;doi:10.1158/1078-0432.CCR-13-1664);Selected as on of the highlights of the issue 2014 Jan;.
|
| Kumar AP. Palmatine suppresses rpS6/NFκB/FLIP to inhibit growth and invasion in androgen independent prostate cancer cells Molecular Carcinogenesis 2014 Jan;.
|
| Chen C-L, Mahalingam D, Osmulski PA, Jadhav RR, Wang C-M, Leach RJ, Weitman SD, Kumar P, Sun L-Z, Gaczynska ME, Thompson J, Huang TH. Single-cell Analysis of Circulating Tumor Cells Identifies Cumulative Expression Patterns of EMT-related Genes in Metastatic Prostate Cancer The Prostate 2013 Jan;73:813-826.
|
Review Article |
| Halff G, Amanda r. Munoz, Divya Chakravarthy, Jingjing Gong, Rita Ghosh, Addanki P. Kumar. Pancreatic Cancer: Current Status and Challenges Current Pharmacology Reports 2017 Oct;3:396-408.
|
| SS Hussain, APKumar and R Ghosh. Food based natural products for cancer management: Is the whole greater than the sum of the parts? Seminars in Cancer Biology 2016 Aug;.
|
| Hussain, SS., Patel, D., Ghosh, R and Kumar AP. Extracting the Benefit of Nexrutine? for Cancer Prevention Curr Pharmacol Rep 2015 Dec;:365-372.
|
| Kumar AP. Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer Molecular Carcinogenesis 2015 Oct;.
|
| Mukherjee,N., Kumar AP and Ghosh R. DNA Methylation and Flavonoids in Genitourinary Cancers Curr Pharmacol Rep 2015 Apr;:112-120.
|
| Kumar, Ph.D. AP. FLIP MOLECULAR SWITCH BETWEEN APOPTOSIS AND NECROPTOSIS Molecular Carcinogenesis 2013 Jan;.
|
| Gong, JJ., Kumar,S., Graham, G, and Kumar, AP. FLIP: Molecular switch between apoptosis and necroptosis Molecular Carcinogenesis (in perspective, DOI 10.1002/MC.22027) 2013 Jan;.
|
